+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Neuropathic Pain Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

  • PDF Icon

    Report

  • 110 Pages
  • August 2022
  • Region: Global
  • Mordor Intelligence
  • ID: 4986960
The Neuropathic Pain market studied is anticipated to grow with a CAGR of nearly 5.5% during the forecast period (2022-2027).

By mid-March, the COVID-19 pandemic had shut down research into neurological diseases worldwide. As a result, the previously rapidly expanding therapeutic pipeline for neurological disorders halted. Public health measures to combat the spread of coronavirus disease 2019 (COVID-19), such as social distancing and shelter-in-place orders, have impacted every stage of therapeutic development, from basic science to manufacturing and distribution of both approved and experimental neurological therapeutics.

Specific factors driving the market growth include the rising prevalence of diabetic neuropathy and other targeted diseases and increasing healthcare expenditure and research funding. As per the International Diabetes Federation (IDF) Diabetes Atlas 10th edition, 537 million adults between 20 years to 79 years will be living with diabetes in 2021. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Diabetic polyneuropathy (DPN) has a lifetime prevalence of nearly 50%, and it is the most common diabetic complication. DPN is a prominent cause of disability due to foot ulceration and amputation, gait disturbance, and fall-related injury. As per the article on Diabetic Neuropathy published in August 2021, Diabetic neuropathy is the most common complication of diabetes mellitus (DM), affecting as many as 50% of patients with type 1 and type 2 DM. DPN significantly lowers the quality of life and substantially increases the health costs associated with diabetes. According to the article published on The True Cost of Diabetes in April 2020, the American Diabetes Association estimates that the economic burden of diabetes includes USD 237 billion in direct medical costs and USD 90 billion in indirect costs due to increased absenteeism at work and reduced productivity.

All these factors above boost the demand for effective medication to treat and cure neuropathic pain.

Key Market Trends


Opioid Holds Significant Share in the Neuropathic Pain Market


Opioids are considered some of the most effective drugs for pain management. Moreover, their use in the direction of severe pain and chronic pain, which are associated with advanced medical illness, is considered standard practice in most parts of the world. An agonist is a drug that triggers specific receptors in the brain. Methadone (potent) agonist therapy is an effective treatment for addiction to opioid medications (such as heroin). Full agonist opioids activate opioid receptors and, after binding tightly, undergo significant conformational changes. Potent agonists include codeine, fentanyl, heroin, hydrocodone, methadone, morphine, and oxycodone.

As per the article “Opioids for Neuropathic Pain” by Palliative Care Network of Wisconsin 2022, meta-analyses suggest opioids have efficacy when prescribed as monotherapy or part of a multi-modal regimen for patients with refractory, function-impairing neuropathies, especially when the prognosis is short. A ceiling effect has been seen when opioids are prescribed for neuropathic pain. The benefit of raising the opioid dose beyond 180-240 mg/day should be sought solely on an individual patient basis.



North America Dominates the Global Neuropathic Pain Market


Due to university and hospital priorities to deal with the COVID-19 (SARS-CoV-2) outbreak as quickly as possible, residency programs have been disrupted. The majority of research and clinical trials have been temporarily halted or postponed. Neurology activities, such as medical training and research, were disrupted due to the pandemic. The COVID-19 pandemic hit drug development for neurological disease hard in 2020, from the disruption of clinical trials due to shelter-in-place orders to the challenges of safely collecting biofluid samples.

In the North American region, the United States has accounted for the largest market share. The presence of significant market players and huge pharmaceutical and biopharmaceutical industries, coupled with the rising investments in the country for the adoption of advanced technologies, is expected to boost the regional growth of the market over the forecast period.

Various initiatives by market players and good government support are also driving the market growth in the region. For instance, the United States Food and Drug Administration approved multiple applications for the first generics of Lyrica (pregabalin), in July 2019, for the management of neuropathic pain linked to diabetic peripheral neuropathy, for the management of postherpetic neuralgia, as adjunctive therapy for the treatment of partial-onset seizures in patients 17 years of age and older, for the management of neuropathic pain associated with spinal cord injury, and for the management of fibromyalgia. The FDA's approval of the first generic versions of pregabalin, a widely prescribed medication, is another example of the agency's longstanding commitment to improving patient access to low-cost, high-quality generic medicines.

Moreover, in July 2019, Cipla Inc. announced that its subsidiary InvaGen Pharmaceuticals had received final approval from the United Stated health regulator for Pregabalin Capsules, indicated for the management of neuropathic pain associated with certain illnesses. Also, in July 2019, Laurus Labs stated that its distribution partner, Rising Pharmaceuticals, has introduced generic Pregabalin capsules to manage neuropathic pain in the American Market.



Competitive Landscape


The global neuropathic pain market is competitive and consists of a few major players. Companies like Grünenthal, Mallinckrodt Pharmaceuticals, GlaxoSmithKline Plc, J Pfizer, Inc., Cipla, Inc., Glenmark, Sun Pharmaceutical Industries Ltd, Teva Pharmaceutical Industries Ltd, among others, hold a substantial market share in the market.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support


This product will be delivered within 2 business days.

Table of Contents

1 INTRODUCTION
1.1 Study Assumptions and Market Definition
1.2 Scope of the Study
2 RESEARCH METHODOLOGY3 EXECUTIVE SUMMARY
4 MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 Rising Prevalence of Diabetic Neuropathy and Other Targetted Diseases
4.2.2 Increasing Healthcare Expenditure and Research Funding
4.3 Market Restraints
4.3.1 Side Effects of Treatments and Availability of Counterfeit Drugs
4.4 Porter's Five Forces Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5 MARKET SEGMENTATION (Market Size by Value - USD million)
5.1 By Indication
5.1.1 Diabetic Neuropathy
5.1.2 Spinal Stenosis
5.1.3 Chemotherapy-induced Peripheral Neuropathy
5.1.4 Others
5.2 By Drug Class
5.2.1 Tricyclic Antidepressants
5.2.2 Opioids
5.2.3 Capsaicin Cream
5.2.4 Steroids
5.2.5 Others
5.3 By Distribution Channel
5.3.1 Hospital Pharmacies
5.3.2 Retail Pharmacies
5.3.3 Others
5.4 Geography
5.4.1 North America
5.4.1.1 United States
5.4.1.2 Canada
5.4.1.3 Mexico
5.4.2 Europe
5.4.2.1 Germany
5.4.2.2 United Kingdom
5.4.2.3 France
5.4.2.4 Italy
5.4.2.5 Spain
5.4.2.6 Rest of Europe
5.4.3 Asia-Pacific
5.4.3.1 China
5.4.3.2 Japan
5.4.3.3 India
5.4.3.4 Australia
5.4.3.5 South Korea
5.4.3.6 Rest of Asia-Pacific
5.4.4 Middle-East and Africa
5.4.4.1 GCC
5.4.4.2 South Africa
5.4.4.3 Rest of Middle-East and Africa
5.4.5 South America
5.4.5.1 Brazil
5.4.5.2 Argentina
5.4.5.3 Rest of South America
6 COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 Grünenthal
6.1.2 Mallinckrodt Pharmaceuticals
6.1.3 GlaxoSmithKline Plc
6.1.4 Pfizer, Inc.
6.1.5 Cipla, Inc. (InvaGen Pharma)
6.1.6 Glenmark
6.1.7 Centaur Pharmaceuticals
6.1.8 Sun Pharmaceutical Industries Ltd.
6.1.9 Teva Pharmaceutical Industries Ltd.
6.1.10 Dr. Reddy's Laboratories Ltd.
6.1.11 Lupin Ltd.
6.1.12 Laurus Labs
6.1.13 Lannett Co Inc
7 MARKET OPPORTUNITIES AND FUTURE TRENDS

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Grünenthal
  • Mallinckrodt Pharmaceuticals
  • GlaxoSmithKline Plc
  • Pfizer, Inc.
  • Cipla, Inc. (InvaGen Pharma)
  • Glenmark
  • Centaur Pharmaceuticals
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Lupin Ltd.
  • Laurus Labs
  • Lannett Co Inc

Methodology

Loading
LOADING...